Diabetic Neuropathy – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Diabetic Neuropathy – Pipeline Review, H2 2018’, provides an overview of the Diabetic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy

– The report reviews pipeline therapeutics for Diabetic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Neuropathy therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics Inc

Angelini Group

Applied Therapeutics Inc

Arena Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celularity Inc

Commence Bio Inc

Grifols SA

Grunenthal GmbH

Immune Pharmaceuticals Inc

Kineta Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Neuralstem Inc

Omeros Corp

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Sphaera Pharma Pte Ltd

Syntrix Biosystems Inc

ViroMed Co Ltd

WEX Pharmaceuticals Inc

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Neuropathy - Overview 6

Diabetic Neuropathy - Therapeutics Development 7

Diabetic Neuropathy - Therapeutics Assessment 15

Diabetic Neuropathy - Companies Involved in Therapeutics Development 23

Diabetic Neuropathy - Drug Profiles 33

Diabetic Neuropathy - Dormant Projects 100

Diabetic Neuropathy - Discontinued Products 103

Diabetic Neuropathy - Product Development Milestones 104

Appendix 113

List of Tables

List of Tables

Number of Products under Development for Diabetic Neuropathy, H2 2018 11

Number of Products under Development by Companies, H2 2018 13

Number of Products under Development by Universities/Institutes, H2 2018 15

Products under Development by Companies, H2 2018 16

Products under Development by Universities/Institutes, H2 2018 18

Number of Products by Stage and Target, H2 2018 20

Number of Products by Stage and Mechanism of Action, H2 2018 22

Number of Products by Stage and Route of Administration, H2 2018 24

Number of Products by Stage and Molecule Type, H2 2018 26

Diabetic Neuropathy – Pipeline by Achelios Therapeutics Inc, H2 2018 27

Diabetic Neuropathy – Pipeline by Angelini Group, H2 2018 27

Diabetic Neuropathy – Pipeline by Applied Therapeutics Inc, H2 2018 27

Diabetic Neuropathy – Pipeline by Arena Pharmaceuticals Inc, H2 2018 28

Diabetic Neuropathy – Pipeline by Bristol-Myers Squibb Co, H2 2018 29

Diabetic Neuropathy – Pipeline by Celularity Inc, H2 2018 29

Diabetic Neuropathy – Pipeline by Commence Bio Inc, H2 2018 29

Diabetic Neuropathy – Pipeline by Grifols SA, H2 2018 30

Diabetic Neuropathy – Pipeline by Grunenthal GmbH, H2 2018 30

Diabetic Neuropathy – Pipeline by Immune Pharmaceuticals Inc, H2 2018 31

Diabetic Neuropathy – Pipeline by Kineta Inc, H2 2018 31

Diabetic Neuropathy – Pipeline by Medifron DBT Co Ltd, H2 2018 31

Diabetic Neuropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018 32

Diabetic Neuropathy – Pipeline by Neuralstem Inc, H2 2018 32

Diabetic Neuropathy – Pipeline by Omeros Corp, H2 2018 33

Diabetic Neuropathy – Pipeline by Reata Pharmaceuticals Inc, H2 2018 34

Diabetic Neuropathy – Pipeline by Relief Therapeutics Holding AG, H2 2018 34

Diabetic Neuropathy – Pipeline by Sphaera Pharma Pte Ltd, H2 2018 34

Diabetic Neuropathy – Pipeline by Syntrix Biosystems Inc, H2 2018 35

Diabetic Neuropathy – Pipeline by ViroMed Co Ltd, H2 2018 35

Diabetic Neuropathy – Pipeline by WEX Pharmaceuticals Inc, H2 2018 36

Diabetic Neuropathy – Pipeline by Yuhan Corp, H2 2018 36

Diabetic Neuropathy – Dormant Projects, H2 2018 104

Diabetic Neuropathy – Discontinued Products, H2 2018 107

List of Figures

List of Figures

Number of Products under Development for Diabetic Neuropathy, H2 2018 11

Number of Products under Development by Companies, H2 2018 12

Number of Products by Top 10 Targets, H2 2018 19

Number of Products by Stage and Top 10 Targets, H2 2018 19

Number of Products by Top 10 Mechanism of Actions, H2 2018 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 21

Number of Products by Routes of Administration, H2 2018 23

Number of Products by Stage and Routes of Administration, H2 2018 23

Number of Products by Molecule Types, H2 2018 25

Number of Products by Stage and Molecule Types, H2 2018 25

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports